Abera Alemayehu, Shifeta Mekdes, Tesfaye Sisay, Addisu Bedasa, Hirigo Agete Tadewos
Clinical Chemistry Unit, Hawassa University Comprehensive Specialized Hospital, Hawassa University, Hawassa, Southern-Ethiopia.
Faculty of Medicine, Department of Paediatrics, Hawassa University, College of Medicine and Health Science, Hawassa, Southern-Ethiopia.
JRSM Cardiovasc Dis. 2024 Aug 16;13:20480040241271789. doi: 10.1177/20480040241271789. eCollection 2024 Jan-Dec.
There is limited information about the extent of metabolic syndrome (MetS) among subjects with cardiac diseases in Ethiopia. Therefore, this study aimed to determine the prevalence and associated factors of MetS among adults with cardiac diseases.
A cross-sectional study was conducted at Hawassa University Comprehensive Specialized Hospital in southern-Ethiopia between May 2021 and August 2021. Data pertaining to the study were collected from 319 participants (153 cardiac and 166 non-cardiac groups) using the WHO stepwise approach. The International Diabetes Federation (IDF) and the revised National Cholesterol Education Program: Adult Treatment Panel III (ATP) were used to define MetS.
The prevalence of MetS was 44.2% and 50.2% in IDF and ATP III, respectively. Among the cardiac group, 54.9% had MetS in IDF criteria, compared to 34.3% in the non-cardiac group ( < .001); whereas, it was 60.1% in the cardiac group and 41% in non-cardiac group ( < .001) by ATP III. Age >60 years, waist-height ratio ≥5, high waist-hip ratio, body mass index 25-29.9 and ≥30 kg/m were significantly associated with higher odds of MetS in both IDF and ATP III. Also, smoking history and monthly income were associated with MetS by ATP III, while being female was associated with higher odds of MetS by IDF.
More than half of the subjects with cardiac diseases developed MetS as compared to non-cardiac controls. Periodic screening and focusing on the identified modifiable high-risk factors such as body weight, smoking, and central adiposity is important to effectively mitigate the risk of further comorbidity and complications in this high-risk population.
在埃塞俄比亚，关于心脏病患者中代谢综合征（MetS）的程度信息有限。因此，本研究旨在确定成年心脏病患者中MetS的患病率及相关因素。
2021年5月至2021年8月在埃塞俄比亚南部的哈瓦萨大学综合专科医院进行了一项横断面研究。使用世界卫生组织的逐步方法从319名参与者（153名心脏病组和166名非心脏病组）收集与研究相关的数据。采用国际糖尿病联盟（IDF）和修订的美国国家胆固醇教育计划：成人治疗小组第三次报告（ATP III）来定义MetS。
根据IDF和ATP III标准，MetS的患病率分别为44.2%和50.2%。在心脏病组中，根据IDF标准，54.9%的患者患有MetS，而非心脏病组为34.3%（<0.001）；而根据ATP III标准，心脏病组为60.1%，非心脏病组为41%（<0.001）。年龄>60岁、腰高比≥5、高腰臀比、体重指数25 - 29.9和≥30 kg/m²在IDF和ATP III中均与MetS的较高几率显著相关。此外，吸烟史和月收入与ATP III定义的MetS相关，而女性与IDF定义的MetS较高几率相关。
与非心脏病对照组相比，超过一半的心脏病患者患有MetS。定期筛查并关注已确定的可改变的高危因素，如体重、吸烟和中心性肥胖，对于有效降低这一高危人群进一步合并症和并发症的风险非常重要。
